CN1915233B - Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation - Google Patents
Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation Download PDFInfo
- Publication number
- CN1915233B CN1915233B CN200610021715A CN200610021715A CN1915233B CN 1915233 B CN1915233 B CN 1915233B CN 200610021715 A CN200610021715 A CN 200610021715A CN 200610021715 A CN200610021715 A CN 200610021715A CN 1915233 B CN1915233 B CN 1915233B
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- cavity disintegration
- starch
- tandospirone
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
A composite medicine in the form particle or oral disintegrating tablet for enxiety is prepared from tandopsirone or its derivative and the pharmacologically acceptable additive. Its oral disintegrating form is also disclosed.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of treating anxiety neurosis, belong to field of medicaments.
Technical background
Anxiety is the common emotional reaction, also is all kinds of neurosal centers symptoms.Along with the development and the rhythm of life of society are accelerated, people increase the increasing demand of anxiolytic drugs.The stimulant medicine of 5-HT receptor---tandospirone (tandospirone, trade name: gain happily quiet) is to be succeeded in developing by SUMITOMO CHEMICAL Pharmaceutical Co., Ltd.Getting permission listing in 1996 in Japan, is with the factory's sale in market of SM-3997 conventional tablet form, does not see the report about other dosage form at present.
Conventional tablet need be by drinking-water and swallowing act completion drug administration process, and this dosage form is for the emergency case patient under some dysphagias or the special environment such as old man, child, coma patient medication, and patient's compliance is poor.Because the afflicted of anxiety neurosis constantly enlarges, simple tablet is difficult to satisfy needs of people, and to adapt to different patients be necessary so prepare multiple dosage form.
Tandospirone belongs to azaspiro ketone (azapirone) type medicine.Wherein the chemical name of structure rafter acid tandospirone is 3a α, 4 β, 7 β; 7a α-6H-2-(4-(4-(2-pyrimidine)-1-piperazine)-butylbenzene)-4,7-methylene-1H-isoindolyl-1,3 (2H)-diketone dihydro citrate [3a α; 4 β; 7 β, 7a α-hexahydro-2 (4-(4-(2-pyrimidinyl)-1-piperazinyl) butyl)-4,7-methano-1H-isoindole-1; 3 (2H)-dione dihydrogen citrate] molecular structural formula is shown in structural formula 3, and the structural formula of tandospirone and derivant thereof is respectively shown in structural formula 1 and 2.
Structural formula 1: the molecular structural formula of tandospirone
Structural formula 2: the molecular structural formula of tandospirone derivant
R is available organic acid or mineral acids such as hydrochloric acid, nitric acid, sulphuric acid, fumaric acid, citric acid, methanesulfonic acid, p-methyl benzenesulfonic acid.
Structural formula 3: the molecular structural formula of SM-3997
Do not see at present relevant report as yet about tandospirone and other peroral dosage form of derivant except that tablet thereof.
Summary of the invention
Technical problem to be solved by this invention provides a kind of pharmaceutical composition of treating anxiety neurosis.
The invention provides a kind of pharmaceutical composition of treating anxiety neurosis, it is that the tandospirone or derivatives thereof that contains effective dose is an active component, adds the preparation that acceptable accessories or complementary composition are prepared from.Tandospirone derivant preferably citric acid tandospirone.
Wherein, said preparation is an oral formulations, comprises solid dispersion, granule, capsule, oral liquid, pill.Tandospirone 3～60mg is contained in every preparation unit in the described preparation, contains tandospirone 3～60mg like the every 0.1g of solid dispersion, granule every bag of (every packed amount is 1g), the every capsule of capsule, the every 10ml of oral liquid, the every ball of pill.
Granule of the present invention is the preparation that is prepared from following weight percentages and adjuvant:
SM-3997 0.05%～6%
Filler 74%～98.95%
Adhesive 1%～10%
Correctives 0%～5%
Coloring agent 0%～5%.
Calculate with 1g with every bag of granule, contain SM-3997 5mg～60mg.
Further, filler is lactose, starch, mannitol in the described granule, and adhesive is 70% ethanol, and correctives is a stevioside; Be the preparation that is prepared from following weight percentages and adjuvant:
SM-3997 1%
Lactose or starch 73%
Mannitol 23%
70% ethanol 2%
Stevioside 1%.
Calculate with every bag of granule 1g, contain SM-3997 10mg.
Solid dispersion of the present invention is that the component that contains following weight percentage ratio is prepared from:
SM-3997 0.8%～60%
Solid dispersion carrier 10%～50%.
Further preferred, solid dispersion is that the component that contains following weight percentage ratio is prepared from:
SM-3997 10%
Solid dispersion carrier 50%.
Wherein, said solid dispersion carrier is mainly the water-solubility carrier material, comprises polyethylene glycols PEG, polyvidone class, surfactant-based, organic acid, saccharide and alcohols, cellulose derivative.
The solid dispersion carrier material should have non-stimulated, nontoxic, not with medicine generation chemical reaction, does not influence the curative effect and the stability of principal agent, can reach the optimum dispersion state, and advantage cheap and easy to get.Carrier material commonly used has water solublity, slightly solubility and enteric solubility carrier material three major types.Water-solubility carrier material commonly used has high molecular polymer (like polyethylene glycols, polyvinylpyrrolidone etc.), surfactant, organic acid and saccharide (like sorbitol, sucrose) etc.; The slightly solubility carrier material has cellulose (like ethyl cellulose), acrylic resin etc.; The enteric solubility carrier material has cellulose family (like cellulose acetate phthalate ester etc.), polyacrylic resin (like II number, III acrylic resin).Because SM-3997 is slightly water-soluble; Absorption than other insoluble or enteric solubility carrier process the dispersion good absorbing of human body to the solid dispersion processed with water-solubility carriers such as PEG found in experiment, so solid dispersion of the present invention is selected water-solubility carriers such as PEG, PVP for use.
Further, the preferred PEG6000 of described solid dispersion carrier, PEG4000, polyvinylpyrrolidone and mixing thereof.
Further preferred, described solid dispersion carrier is PEG6000.
The present invention also provides a kind of oral cavity disintegration preparation of treating anxiety neurosis, and it is the solid dispersion by above-mentioned effective dose, adds the preparation that disintegrating agent and the adjuvant of pharmaceutically using always or complementary composition are prepared from.
Described disintegrating agent is low-substituted hydroxypropyl methylcellulose (L-HPC), crospolyvinylpyrrolidone (PPVP), carboxymethyl starch sodium (CMS-Na) and composition thereof.
Filler can be selected starch, Icing Sugar, dextrin, lactose, amylum pregelatinisatum, microcrystalline Cellulose, inorganic salts, mannitol, xylitol, sorbitol etc.
Adhesive comprises distilled water, ethanol, starch slurry, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, hypromellose, 5%～20% gelatin solution; 50%～70% sucrose solution, 3%～5% polyethylene adjoin aqueous solution or alcoholic solution of pyrrolidone (PVP) etc.
Correctives can be selected natural or artificial sweetening agents such as edulcorant protein sugar, aspartame or aromatic Mentholum, acidic flavoring agent citric acid, essence, mannitol, stevioside.
Lubricant can be selected magnesium stearate, micropowder silica gel, Stepanol MG, Pulvis Talci hydrogenated vegetable oil, polyethylene glycols and magnesium laurylsulfate etc.
Coloring agent comprises, pharmaceutically available color lake and pigments such as ferrum oxide, titanium dioxide, sunset yellow, tartrazines, capsanthin, carotene, fast green, chlorophyll.
Further, described oral cavity disintegration preparation is tablet, capsule, granule.
Oral cavity disintegration preparation of the present invention is the preparation that is prepared from following weight percentages and adjuvant:
SM-3997 0.8%～60%
Solid dispersion carrier 10%～50%
Filler 0%～79.2%
Disintegrating agent 10%～20%
Correctives 0%～10%
Lubricant 0%～5%
Coloring agent 0%～5%.
Wherein, preferably citric acid tandospirone, solid dispersion carrier, disintegrating agent use with 1: 5: 2 compatibility of weight proportion.
Oral cavity disintegration tablet of the present invention is with 100～600mg sheet restatement, and every contains SM-3997 5～60mg; Capsule of the present invention, every capsule contains SM-3997 5～60mg; The every gram of granule of the present invention contains SM-3997 5～60mg.
Further, in the oral cavity disintegration preparation of the present invention, the solid dispersion carrier is PEG6000, and disintegrating agent is low-substituted hydroxypropyl methylcellulose (L-HPC), and filler is that lactose starch, correctives are that stevioside, lubricant are that magnesium stearate, coloring agent are carotene; Oral cavity disintegration preparation is the preparation that is prepared from following weight percentages and adjuvant:
SM-3997 10%
PEG6000 50％
Low-substituted hydroxypropyl methylcellulose (L-HPC) 20%
Lactose starch 16%
Stevioside 1%
Magnesium stearate 1.5%
Carotene 1.5%.
Oral cavity disintegration tablet of the present invention is with 100mg sheet restatement, and every contains SM-3997 10mg; Capsule of the present invention, every capsule contains SM-3997 10mg; Granule of the present invention is in every bag of 1g, and every 1g contains SM-3997 10mg.
Preferred particulates agent of the present invention and oral cavity disintegration tablet.Tandospirone granule of the present invention and oral cavity disintegration tablet are compared with other conventional peroral dosage form, can reduce dysphagia; Improve compliance; Being applicable to the special population medication, is the old man easily, and child and the patient with some psychotic and the difficult change of bed position that dysphagia is arranged accept; And owing to selected proper supplementary material, make the product mouthfeel good, avoid the bitterness of SM-3997.And oral cavity disintegration preparation of the present invention can be at direct drug injection under the water-less environment; There is not trapping phenomena at digestive tract, little to GI irritation; Discharge soon, absorb soon, a kind of new selection is provided for clinical.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement and the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
Below, foregoing of the present invention is done further detailed description again through the specific embodiment of embodiment form.But should this be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following instance.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
The capsule of embodiment 1 tandospirone (1000 capsules)
Tandospirone 3g (about 0.008mol)
Starch 200g
Microcrystalline Cellulose 5g
Hydrochloric acid tandospirone and starch through behind the equivalent incremental method mixing, again with the microcrystalline Cellulose mixing, are granulated, encapsulated, promptly get capsule.
The granule of embodiment 2 SM-3997s (1000 bags of granules)
SM-3997 10g (about 0.17mol)
Lactose 730g
Mannitol 230g
The about 20ml of 70% ethanol
Stevioside 10g
Method for making: SM-3997 and lactose starch and mannitol are through equivalent incremental method mixing, and again with other auxiliary materials and mixing, granulating promptly gets.
The granule of embodiment 3 SM-3997s (1000 bags of granules)
SM-3997 5g (about 0.008mol)
Starch 2000g
Icing Sugar 2000g
Dextrin 2000g
Soluble starch 4000g
Stevioside 10g
Method for making: SM-3997 and dextrin are through equivalent incremental method mixing, and again with other auxiliary materials and mixing, granulating promptly gets.
The granule of embodiment 4 SM-3997s (1000 bags of granules)
SM-3997 60g (about 0.10mol)
Icing Sugar 400g
Dextrin 200g
Soluble starch 400g
Stevioside 1g
Method for making: SM-3997 and dextrin are through equivalent incremental method mixing, and again with other auxiliary materials and mixing, granulating promptly gets.
The oral cavity disintegration tablet of embodiment 5 SM-3997s (1000)
SM-3997 10g
PEG6000 100g
Low-substituted hydroxypropyl methylcellulose (L-HPC) 40g
Lactose starch 32g
Stevioside 2g
Magnesium stearate 1.5g
Carotene 2g.
Method for making: 1. supplementary material is crossed 100 mesh sieves respectively
2. with SM-3997 and low-substituted hydroxypropyl methylcellulose mix homogeneously in blender of recipe quantity; Continue the equivalent surplus low-substituted hydroxypropyl methylcellulose that progressively increases; Mix homogeneously adds lactose starch then, stevioside, magnesium stearate, carotene mix homogeneously.
3. mensuration content calculates sheet and weighs, and direct powder compression is made 1000 altogether, control hardness 1.5～2.5kg.
4. check, packing, warehouse-in.Attention: answer controlled humidity below 50%.
The oral cavity disintegration tablet of embodiment 6 SM-3997s (1000)
SM-3997 5g (about 0.008mol)
PEG4000 60g
Carboxymethyl starch sodium 60g
Lactose starch 310.5g
Mannitol 160g
Magnesium stearate 4.5g
Method for making: 1. supplementary material is crossed 100 mesh sieves respectively
2. SM-3997 and the PEG4000 with recipe quantity processes solid dispersion; Then with carboxymethyl starch sodium mix homogeneously in blender, continue the equivalent surplus carboxymethyl starch sodium that progressively increases, mix homogeneously; After add lactose starch, mannitol successively, add the magnesium stearate mix homogeneously at last.
3. mensuration content calculates sheet and weighs, and direct powder compression is made 1000 altogether, control hardness 1.5～2.5kg.
4. check, packing, warehouse-in.Attention: answer controlled humidity below 50%.
The oral cavity disintegration tablet of embodiment 7 SM-3997s (1000)
SM-3997 60g (about 0.10mol)
Carboxymethyl starch sodium 30g
Lactose starch 8.5g
Orange flavor 1g
Magnesium stearate 1.5g
Method for making: 1. supplementary material is crossed 100 mesh sieves respectively
2. with SM-3997 and carboxymethyl starch sodium mix homogeneously in blender of recipe quantity, continue the equivalent surplus carboxymethyl starch sodium that progressively increases, mix homogeneously, after add lactose starch successively, add orange flavor and magnesium stearate mix homogeneously at last.
3. mensuration content calculates sheet and weighs, and direct powder compression is made 1000 altogether, control hardness 1.5～2.5kg.
4. check, packing, warehouse-in.Attention: answer controlled humidity below 50%.
The pill of embodiment 8 hydrochloric acid tandospirone (1000 pills)
Hydrochloric acid tandospirone 45g (about 0.11mol)
Mannitol 1.5g
Distilled water 500ml
Starch 40g
Dextrin 20g
Through behind the equivalent incremental method mixing, again with dextrin, correctives mixing, weary ball is drying to obtain with hydrochloric acid tandospirone and starch.
The oral liquid of embodiment 9 hydrochloric acid tandospirone (100 bottles of oral liquids)
Hydrochloric acid tandospirone 45g (about 0.11mol)
Mannitol 50g
Distilled water 1000ml
Rich horse tandospirone and mannitol mixing, adding distil water promptly gets to 1000ml.
The following beneficial effect through evidence pharmaceutical composition of the present invention.
The proportion optimization experiment of experimental example 1 granule
The prescription screening experiment (SM-3997 0.027mol) of table 1 granule
| Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 | Prescription 6 | Prescription 7 | |
| SM-3997 | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg |
| Lactose starch | 90mg | 750mg | 750mg | 750mg | 750mg | ||
| Mannitol | 240mg | 230mg | 230mg | 220mg | |||
| Starch | 990mg | ||||||
| Lactose | 990mg | ||||||
| Stevioside | 10mg | 20mg | |||||
| Citric acid | 10mg | ||||||
| Outward appearance | Slightly coarse | Slightly coarse | Bright and clean | Bright and clean | Bright and clean | Bright and clean | Bright and clean |
| Mouthfeel | Bitter and puckery flavor | Bitter and puckery flavor | Bitter and puckery flavor | Slightly bitter | Sour in the mouth | Good | It is too sweet to distinguish the flavor of |
| Weight differential | Defective | Defective | Qualified | Qualified | Qualified | Qualified | Qualified |
| Dissolution (%) | 88.23 | 90.90 | 90.12 | 91.03 | 91.27 | 92.45 | 92.41 |
| Overall merit | Outward appearance is bad, flowability is bad, and mouthfeel is bad | Outward appearance, flowability, mouthfeel are all relatively poor | Mobile, mouthfeel is bad | Outward appearance, good fluidity, mouthfeel are bad | Outward appearance, good fluidity, mouthfeel are bad | Outward appearance, good fluidity, mouthfeel are good | Outward appearance, good fluidity, mouthfeel are bad |
Can find out that by table 1 lactose starch can improve the outward appearance of granule as adjuvant.The adding of mannitol can improve its taste and weight differential.The adding of stevioside helps to improve its taste.Take all factors into consideration prescription 7, mouthfeel, dissolution, outward appearance, flowability are all better.And best proportioning is SM-3997 1% (calculate with 10mg, every bag of 1g calculates), lactose starch 75%, and mannitol 23%, 70% ethanol is an amount of, stevioside 1%.
The prescription screening experiment of experimental example 2 oral cavity disintegration tablets
The prescription screening experiment (SM-3997 0.027mol) of table 2 oral cavity disintegration tablet
| Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 | Prescription 6 | Prescription 7 | Prescription 8 | Prescription 9 | Prescription 10 | |
| SM-3997 | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg | 15.8mg |
| PEG6000 | 50mg | 100mg | 50mg | 50mg | 50mg | 50mg | 50mg | |||
| PEG4000 | 50mg | |||||||||
| Ethyl cellulose | 50mg | |||||||||
| The cellulose acetate phthalate ester | 50mg | |||||||||
| L-HPC | 10mg | 30mg | 20mg | |||||||
| CMS-Na | 20mg | |||||||||
| Dried starch | 20mg | |||||||||
| Lactose starch | 16mg | 16mg | 16mg | 16mg | 16mg | 16mg | 16mg | 16mg | 16mg | 16mg |
| Dispersion | Bad | Bad | Bad | Good | Good | Good | Good | Good | Good | Good |
| Outward appearance | Slightly coarse | Slightly coarse | Bright and clean | Bright and clean | Bright and clean | Bright and clean | Bright and clean | Bright and clean | Bright and clean | Bright and clean |
| Disintegration (s) | - | - | - | - | ?- | 55 | 45 | 45 | 26 | 28 |
| Mouthfeel | - | - | - | - | ?- | Good | Good | Good | The grittiness sense | Good |
| Overall merit | - | - | - | - | ?- | Outward appearance, good fluidity, mouthfeel are good | Outward appearance is good, flowability is bad, mouthfeel is bad | Outward appearance, good fluidity, mouthfeel are good |
By finding out in the table; In the dispersion carrier; The dispersion of water-solubility carriers such as selection PEG is superior to insoluble and the enteric solubility material; To be superior to PEG4000. and proportioning raw materials be that the dispersion of 1: 5 and 1: 10 has no difference basically to PEG6000 in the water-soluble material, and best proportioning is selected to be at 1: 5 by institute the present invention.Select to be superior to disintegration of L-HPC CMS-Na and dried starch in the disintegrating agent; And investigation through its dosage; The proportioning of finding solid dispersion carrier and disintegrating agent is 5: 2 o'clock; No matter dispersion or disintegration are optimum state, so crude drug among the present invention: the solid dispersion carrier: the optimum weight proportioning of disintegrating agent is 1: 5: 2.
Claims (1)
1. pharmaceutical composition of treating anxiety neurosis is characterized in that: it is to be the oral cavity disintegration tablet that active component is prepared from SM-3997, and wherein, every is prepared from following raw material medicaments and adjuvant:
Wherein, described PEG6000 is the solid dispersion carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610021715A CN1915233B (en) | 2006-08-30 | 2006-08-30 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610021715A CN1915233B (en) | 2006-08-30 | 2006-08-30 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1915233A CN1915233A (en) | 2007-02-21 |
| CN1915233B true CN1915233B (en) | 2012-10-03 |
Family
ID=37736392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610021715A Active CN1915233B (en) | 2006-08-30 | 2006-08-30 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1915233B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440491A (en) * | 2021-08-17 | 2021-09-28 | 江苏百奥信康医药科技有限公司 | Tandospirone controlled-release orally disintegrating tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998042344A1 (en) * | 1997-03-24 | 1998-10-01 | R. P. Scherer Limited | Pharmaceutical composition |
| CN1339972A (en) * | 1999-02-15 | 2002-03-13 | 住友制药株式会社 | Tablets quickly disintegrated in the oral cavity |
| CN1523980A (en) * | 2000-12-07 | 2004-08-25 | ��̹��ҽҩ��˾ | Pharmaceutical preparation comprising an active dispersed on a matrix |
-
2006
- 2006-08-30 CN CN200610021715A patent/CN1915233B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998042344A1 (en) * | 1997-03-24 | 1998-10-01 | R. P. Scherer Limited | Pharmaceutical composition |
| CN1339972A (en) * | 1999-02-15 | 2002-03-13 | 住友制药株式会社 | Tablets quickly disintegrated in the oral cavity |
| CN1523980A (en) * | 2000-12-07 | 2004-08-25 | ��̹��ҽҩ��˾ | Pharmaceutical preparation comprising an active dispersed on a matrix |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1915233A (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101516344A (en) | Pharmaceutical compositions comprising nilotinib or its salt | |
| WO2000020033A1 (en) | Tablets immediately disintegrating in the oral cavity | |
| CN1911211B (en) | Solid oral preparation of leishajilan | |
| AU729437B2 (en) | Cefadroxil monohydrate tablet formulation | |
| CN103536568A (en) | Orally disintegrating tablets containing lurasidone and preparation method thereof | |
| CN101277721B (en) | Orally disintegrating tablet | |
| TW201302198A (en) | Formulations containing nalbuphine and uses thereof | |
| CN101822672A (en) | Compound with metformin and repaglinide, preparation method thereof and application thereof | |
| CN101716132B (en) | Febuxostat enteric preparation | |
| CN102451162A (en) | Olanzapine medicine absorbed through oral mucosa | |
| CN1915233B (en) | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102860986A (en) | Stable taste-masking levocetirizine medicine composition and preparation method thereof | |
| CN102727455A (en) | Tadalafil oral disintegrating tablet and preparation method thereof | |
| CN107625734B (en) | Water-free swallow taste masking preparation and preparation method thereof | |
| CN112957334B (en) | Pharmaceutical composition containing ALPELISIB | |
| CN101444513B (en) | Cefaclor orally disintegrating tablet and preparation method thereof | |
| AU2013347264B2 (en) | Dispersible tablet | |
| EP2481395A1 (en) | Sachet, effervescent tablet and dry syrup of otilonium | |
| CN102614140B (en) | Iloperidone oral cavity disintegration tablet and preparation method thereof | |
| CN100464744C (en) | Orally disintegrated Ubenimex tablet and its prepn process | |
| CN104434860A (en) | Ambroxol hydrochloride osmotic pump type pharmaceutical composition prepared by inclusion process | |
| JPH11116465A (en) | Rapidly dissolvable preparation and its production | |
| JP2003095981A (en) | Medicine composition | |
| CN1321645C (en) | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 646000 national high tech Zone, Sichuan, Luzhou Province Pharmaceutical Industrial Park Patentee after: Sichuan Keruide pharmaceutical Limited by Share Ltd Address before: 646106 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: Keruide Pharmaceutical Co., Ltd., Sichuan |